Hyperthermia-induced ablation is emerging as a less invasive and more efficient alternative to surgical means of removing solid tumors or hyperplastic tissues. Most hyperthermic technologies available rely on metal-based compounds, which are less thermally stable and do not catabolize in the body. This novel hyperthermic technology offers a soluble compound capable of heating and ablating unwanted tissues for a wide range of applications while producing minimal biocompatibility issues.
Researchers at Wake Forest University and Wake Forest School of Medicine have developed novel soluble hyperthermic particles that are capable of generating hyperthermia to destroy cancer cells. Upon stimulation with a laser, the particles produce heat, which has been shown to reduce total colorectal cancer cell viability to 5-10%. This technology has potential for use in the treatment of cancer or other diseases involving hyperplastic tissue.
- The technology is water soluble and capable of catabolizing in the body, unlike similar technologies that are metal based and non-biodegradable.
- The technology is thermally stable, whereas metal-based nanoparticles can be melted during the hyperthermic process, leading to a loss of heating efficiency.
- Destruction of hyperplastic tissue in diseases such as cancer, benign prostatic hyperplasia (BPH), endometriosis and fibroid growths
- Reduction of cellulite and varicose veins for aesthetic uses
- May be used for improving drug delivery methods
Stage of Development
- The technology has been validated in vitro using HCT116 and RKO colorectal cancer cells.
- In vivo animal testing is currently ongoing.
- Nicole Levi, PhD
- Christopher MacNeill, PhD
- David L. Carroll, PhD
Charlie Shaw, PhD